loading page

Cancer treatment-related cardiotoxicity: A focus on sacubitril/valsartan
  • +3
  • feng hu,
  • Huajiong Yu,
  • Weiping Du,
  • Mengjia Chen,
  • Jia Su,
  • Xiaomin Chen
feng hu

Corresponding Author:[email protected]

Author Profile
Huajiong Yu
Zhejiang Shuren University
Author Profile
Weiping Du
Ningbo City First Hospital
Author Profile
Mengjia Chen
Zhejiang University School of Medicine First Affiliated Hospital
Author Profile
Xiaomin Chen
Author Profile


Cardiotoxicity is the most dramatic complications of cancer therapies, leading to halt in potentially life-saving anti-tumor treatment regimens and a poor survival prognosis in a non-negligible percentage of patients. Angiotensin converting enzyme inhibitors (ACEIs) and β-blockers are effective in the treatment of the cancer therapy–related cardiac dysfunction (CTRCD), while their roles in the prevention of cardiotoxicity are unclear. Sacubitril/valsartan was advantageous over ACEI in heart failure patients for further reduction of cardiovascular death or heart failure re-hospitalization. However, there is short of well-established testimony of its efficacy and safety in the prevention and treatment of CTRCD in the cardio-oncology setting. Although some small observational studies found a good performance of sacubitril/valsartan in patients with CTRCD, large-scale prospective clinical studies are required to confirm its excellent results. In this paper, we review the potential benefit of sacubitril/valsartan in human subjects with CTRCD.